Latest information on COVID-19
Support teaching, research, and patient care.
Joseph C. Wu, MD, PhD is Director of the Stanford Cardiovascular Institute (http://cvi.stanford.edu/) and the Simon H. Stertzer, MD, Professor of Medicine and Radiology. Dr. Wu received his medical degree from Yale. He completed his medicine internship, residency and cardiology fellowship training at UCLA followed by a PhD (Molecular & Medical Pharmacology) in the UCLA STAR program. His clinical interests involve adult congenital heart disease and cardiovascular imaging. His lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). The main goals are to (i) understand mechanisms of cardiovascular diseases, (ii) accelerate drug discovery, (iii) develop “clinical trial in a dish” concept, and (iv) implement precision medicine for cardiovascular patients. His lab uses a combination of stem cells, genomics, epigenetics, cellular & molecular biology, physiological testing, and molecular imaging technologies. Dr. Wu has published >450 manuscripts with H-index of 108 on Google scholar. He is listed as top 1% highly cited researchers in Web of Science (2018, 2019 & 2020). Among his trainees, >35 of them are principal investigators in the US or abroad (http://med.stanford.edu/wulab.html).Dr. Wu has received numerous awards, including the National Institutes of Health (NIH) Director’s New Innovator Award, NIH Roadmap Transformative Award, American Heart Association (AHA) Innovative Research Award, Presidential Early Career Award for Scientists and Engineers (PECASE) given by President Obama, AHA Established Investigator Award, Burroughs Wellcome Foundation Innovation in Regulatory Science Award, AHA Distinguished Scientist Award, and AHA Merit Award. Dr. Wu serves on the FDA Cellular Tissue and Gene Therapies Advisory Committee. Dr. Wu is an elected member of American Society of Clinical Investigators (ASCI), Association of University Cardiologists (AUC), American Institute for Medical and Biological Engineering (AIMBE), American Association of Physicians (AAP), American Association for the Advancement of Science (AAAS), and National Academy of Medicine (NAM).
My lab works on biological mechanisms of adult stem cells, embryonic stem cells, and induced pluripotent stem cells. We use a combination of gene profiling, tissue engineering, physiological testing, and molecular imaging technologies to better understand stem cell biology in vitro and in vivo. For adult stem cells, we are interested in monitoring stem cell survival, proliferation, and differentiation. For ESC, we are currently studying their tumorigenicity, immunogenicity, and differentiation for regenerative medicine. For iPSC, we are focusing on disease modeling, drug discovery, and personalized medicine.
An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)
This study is designed to assess the efficacy, safety and tolerability of ixmyelocel-T
compared to placebo (vehicle control) when administered via transendocardial catheter-based
injections to patients with end stage heart failure due to IDCM, who have no reasonable
revascularization options (either surgical or percutaneous interventional) likely to provide
View full details
NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction
This study will assess the safety and efficacy of intracoronary artery administered
autologous bone marrow derived stem cells in subjects post ST segment elevation myocardial
infarction (STEMI). This will be assessed by evaluating and comparing the autologous stem
cell treatment group to the control group in terms of the occurrence of AE's, SAE's and Major
Adverse Cardiac Events (MACE), by the change in myocardial perfusion (RTSS) measured
quantitatively by gated single photon emission computed tomography myocardial perfusion
imaging (gated SPECT MPI), and other secondary endpoints such as LVEF measured by cardiac MRI
in addition to other endpoints.